Share on StockTwits

Cubist Pharmaceuticals (NASDAQ:CBST) Director Nancy J. Hutson sold 9,000 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $65.00, for a total value of $585,000.00. Following the completion of the sale, the director now directly owns 5,951 shares of the company’s stock, valued at approximately $386,815. The sale was disclosed in a filing with the SEC, which is available at this link.

Cubist Pharmaceuticals (NASDAQ:CBST) traded down 1.22% on Wednesday, hitting $65.4101. 247,462 shares of the company’s stock traded hands. Cubist Pharmaceuticals has a one year low of $58.50 and a one year high of $82.12. The stock has a 50-day moving average of $64.44 and a 200-day moving average of $69.36. The company has a market cap of $4.954 billion and a P/E ratio of 580.88.

Cubist Pharmaceuticals (NASDAQ:CBST) last posted its quarterly earnings results on Tuesday, July 22nd. The company reported $0.23 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.01 by $0.22. The company had revenue of $294.40 million for the quarter, compared to the consensus estimate of $299.60 million. During the same quarter last year, the company posted $0.42 earnings per share. Cubist Pharmaceuticals’s revenue was up 13.8% compared to the same quarter last year. On average, analysts predict that Cubist Pharmaceuticals will post $0.71 earnings per share for the current fiscal year.

A number of research firms have recently commented on CBST. Analysts at Zacks downgraded shares of Cubist Pharmaceuticals from a “neutral” rating to an “underperform” rating in a research note on Monday. They now have a $58.00 price target on the stock. Separately, analysts at JMP Securities downgraded shares of Cubist Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, July 23rd. They now have a $80.00 price target on the stock. Finally, analysts at Aegis reiterated a “positive” rating on shares of Cubist Pharmaceuticals in a research note on Monday, June 23rd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $79.64.

Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.